Extracorporeal Membrane Oxygenation
Conditions
Keywords
Extracorporeal Membrane Oxygenation, Pharmacokinetics, Hydromorphone
Brief summary
The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.
Detailed description
A population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO was established. The patients were given hydromorphone 0.03mg/kg/h by continuous intravenous infusion for 72 hours for analgesia. Blood samples were collected at different time points before and after administration, and quantitative liquid chromatography tandem mass spectrometry was used to detect hydromorphone and its main metabolite, hydromorphone-3-glucuronide.
Interventions
DRUGHydromorphone
Hydromorphone was administered intravenously at a rate of 0.03 mg/kg/h for 72 h for analgesia. Blood samples were collected before administration and at different time points after administration, and the contents of hydromorphone and hydromorphone-3-glucuronide (main metabolite) were detected by quantitative liquid chromatography tandem mass spectrometry, and then A population pharmacokinetic model of hydromorphone in patients under ECMO was established.
Sponsors
Xiaobo Yang, MD
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Between the ages of 18 and 80; * Using hydromorphone for pain relief; * Using ECMO for more than 96h
Exclusion criteria
* Allergic to hydromorphone; * Use of CRRT during ECMO; * Liver function Child-Pugh B, C grade; * Pregnancy; * Intestinal obstruction; * Refused to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volume of distribution of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO | Within 4 days | Quantitative liquid chromatography-tandem mass spectrometry was used to detect the contents of hydromorphone and hydromorphone -3- glucuronide in blood samples at various time points, so as to obtain the pharmacokinetics of continuous intravenous infusion of hydromorphone for 72 hours during ECMO. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clearance of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO | Within 4 days | Clearance of hydromorphone and hydromorphone-3-glucuronide in patients on ECMO |
Countries
China
Contacts
Primary ContactYou Shang, Prof.
Outcome results
None listed